

## ABOUT HELIX BIOPHARMA

# THE COMPANY




























Helix BioPharma Corp. is a Canadian, clinical-stage oncology company domiciled in Toronto, Ontario and listed on the TSX under the ticker symbol “HBP”, on OTC PINK under “HBPCD” and on FWB under the symbol “HBP0”.

The Company is on a mission to level the playing field against cancer’s biggest, most urgent challenges by **innovating from strength.**

At Helix, innovating from strength means taking a pragmatic approach to innovation; our growing, world-class team focuses its efforts on where we need a head start and which calculated risks are worth taking to bring effective, urgently needed treatments to patients battling prevalent, hard-to-treat cancers.

## CORE TEAM

PREVIOUSLY:

	<b>Thomas Mehrling, MD, PhD</b> CEO	  
	<b>Veronika Kandziora</b> COO	  
	<b>Rohit Babbar, CPA, CA</b> CFO	  
	<b>Davide Guggi, PhD</b> CTO	  
	<b>Brenda Lee, PhD</b> Director: Clinical Operations	  
	<b>Jonathan Davis, PhD</b> Director: ADC Discovery	  
	<b>Kim Gaspar, PhD</b> Director: Quality Assurance	 



### OUR VISION


To shape a near future where today’s hard-to-treat cancers are vincible.



### OUR MISSION

To level the playing field against cancer’s biggest, most urgent challenges by honing young drug candidates with great potential and a head start into first- and best-in-class oncology medicines.

### CANCERS WE ARE TARGETING, GLOBAL INCIDENCE (MILLIONS)



WHO GLOBOCAN, 2022

### MORTALITY (DECEASED 5 YEARS FROM DIAGNOSIS)



American Cancer Society, (2024).

Brandwein et al, 2020.

Pancreatic Cancer Action Network (2024).

## OUR ASSETS



### CEACAM6 PLATFORM

Bio-conjugates that score with precision against prevalent, hard-to-treat cancers over-expressing carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6).

#### 1) TUMOR DEFENCE BREAKER™, L-DOS47

An antibody-enzyme conjugate (AEC) that takes the brakes of anti-tumor immunity and delivers a game-changing assist to today’s leading immunotherapies.

#### 2) C6 RDCs and ADCs

Radionuclide drug conjugates (RDCs) and bi-specific antibody-drug conjugates (ADCs) designed to outsmart resistant tumors expressing CEACAM6 and break new ground in therapeutic efficacy.

### PRE-IND CANDIDATES

#### 3) LEUMUNA™





An oral immune checkpoint modulator to bring long-term remission within reach for patients relapsing with leukemia after allogeneic stem cell transplantation.

#### 4) GEMCEDA™

A first-in-class oral gemcitabine to enrich the spectrum of disease-limiting and life-enhancing outcomes for patients whose cancer has progressed.


# HOW WE WANT TO MOVE THE NEEDLE

ASSETS IN ORDER OF STAGE OF DEVELOPMENT

CANDIDATE	L-DOS47	LEUMUNA™	GEMCEDA™	C6 RDCs & ADCs
LEAD INDICATION	 Non-small cell lung cancer (NSCLC)	 Leukemia relapse	 Advanced solid tumors	 Solid tumors
NEXT MILESTONE	PHASE IB IND (2025)	PHASE I/II IND (2026)	PHASE I/II IND (2026)	PATENT FILINGS (2025)
GOAL	Add ≥30% efficacy to checkpoint inhibitors	Long-term remission (2+ years) or cure	Significant increase in progression-free survival	Overcome resistance, maximize efficacy
PATENT LIFE	2036 + extensions	2041	2043	2045
HOW IT INNOVATES FROM STRENGTH	Enhances efficacy of latest standard of care (immunotherapy)	Backed by clinical safety and efficacy data + FDA Orphan Designation	WHO Essential Medicine with oral bioavailability on par with IV (90%)	Leveraging latest state-of-the-art ADC technology and CEACAM6 know-how

## INVESTMENT & RETURN

CURRENTLY UNDERVALUED, WITH MAJOR VALUE INFLECTION POINTS APPROACHING





## FOCUSED, AMBITIOUS PLAN AHEAD

- 1) USD 80 million capital raise
- 2) Phase IB in NSCLC first-patient-in in 2025
- 3) Relocation to the US and NASDAQ listing
- 4) Grow world-class team
- 5) Near-term partnering/exits

Shaping a near future where today's hard-to-treat cancers are *vincible*.

HELIX BIOPHARMA CORP.  
Bay Adelaide Centre – North Tower  
40 Temperance Street, Suite 2  
Toronto, ON M5H 0B4  
Tel: +1 857 208 7687  
Thomas Mehrling, CEO  
corporate@helixbiopharma.com

TSX: HBP  
OTC PINK: HBPCD  
FRANKFURT: HBPO

 [www.helixbiopharma.com](http://www.helixbiopharma.com)  
 [Helix BioPharma Corp.](https://www.linkedin.com/company/helix-biopharma)

For investor relations, contact [corporate@helixbiopharma.com](mailto:corporate@helixbiopharma.com)